Why the study?
Does ivabradine improve heart rate reduction and tolerability compared to beta-blockers in heart transplant recipients?
Does ivabradine improve heart rate reduction and tolerability compared to beta-blockers in heart transplant recipients?
Ivabradine may offer symptomatic benefit and better tolerability than beta-blockers for heart rate reduction in heart transplant recipients, particularly in cases of beta-blocker intolerance.
May support ivabradine for heart rate control in beta-blocker-intolerant recipients; leaves open confirmation in randomized trials.
Heart rate reduction with ivabradine is effective and potentially better tolerated than beta-blocker therapy in heart transplant recipients. Although the prognostic role of heart rate after HTX is unknown, ivabradine may offer relevant symptomatic benefit, especially in cases of beta-blocker intolerance.
No takes yet. Share an insight, caveat, or question.
Doesch et al. (2007) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: